EA201991870A1 - Лечение рака мочевого пузыря с помощью антитела к pd-l1 - Google Patents
Лечение рака мочевого пузыря с помощью антитела к pd-l1Info
- Publication number
- EA201991870A1 EA201991870A1 EA201991870A EA201991870A EA201991870A1 EA 201991870 A1 EA201991870 A1 EA 201991870A1 EA 201991870 A EA201991870 A EA 201991870A EA 201991870 A EA201991870 A EA 201991870A EA 201991870 A1 EA201991870 A1 EA 201991870A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bladder cancer
- antibody
- subject
- methods
- treatment
- Prior art date
Links
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 8
- 206010005003 Bladder cancer Diseases 0.000 title abstract 7
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract 7
- 102000008096 B7-H1 Antigen Human genes 0.000 title abstract 3
- 108010074708 B7-H1 Antigen Proteins 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229950009791 durvalumab Drugs 0.000 abstract 1
- 238000009093 first-line therapy Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 238000011301 standard therapy Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
- 229950007217 tremelimumab Drugs 0.000 abstract 1
- 208000023747 urothelial carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Abstract
Предусмотрены способы лечения рака мочевого пузыря (например, уротелиальной карциномы, UC) у субъекта, имеющего рак мочевого пузыря, например UC, с помощью эффективной схемы дозирования антитела к PD-L1, например дурвалумаба, или его антигенсвязывающего фрагмента. Также предусмотрены способы, в которых антитело к PD-L1 применяют в комбинации с другим иммунотерапевтическим средством, например тремелимумабом, для лечения рака мочевого пузыря, например UC, у субъекта, имеющего рак мочевого пузыря. В некоторых случаях у субъекта, проходящего лечение, идентифицировано наличие рака или опухоли мочевого пузыря, характеризующихся низким/отсутствующим уровнем PD-L1 или высоким уровнем PD-L1. Также предусмотрены способы, в которых лечение рака мочевого пузыря с помощью антитела к PD-L1 применяют после стандартной терапии или терапии первой линии у субъектов, у которых наблюдалось прогрессирование после таких видов терапии или у которых произошел рецидив после предыдущей схемы лечения.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991870A1 true EA201991870A1 (ru) | 2020-02-12 |
Family
ID=63169615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991870A EA201991870A1 (ru) | 2017-02-16 | 2018-02-16 | Лечение рака мочевого пузыря с помощью антитела к pd-l1 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (ru) |
| EP (1) | EP3582805A4 (ru) |
| JP (2) | JP2020507596A (ru) |
| KR (2) | KR20190117014A (ru) |
| CN (1) | CN110290803A (ru) |
| AU (1) | AU2018221822A1 (ru) |
| CA (1) | CA3052652A1 (ru) |
| EA (1) | EA201991870A1 (ru) |
| IL (2) | IL302777A (ru) |
| MA (1) | MA47509A (ru) |
| SG (1) | SG11201907211TA (ru) |
| WO (1) | WO2018152415A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3142751T3 (pl) * | 2014-05-13 | 2019-12-31 | Medimmune Limited | Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| CN115667552A (zh) * | 2020-05-21 | 2023-01-31 | 阿斯利康(瑞典)有限公司 | 与对局部晚期或转移性尿路上皮癌中的免疫疗法敏感性相关的肿瘤突变负荷 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| PL3142751T3 (pl) * | 2014-05-13 | 2019-12-31 | Medimmune Limited | Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca |
| KR20180012753A (ko) * | 2015-05-29 | 2018-02-06 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
| JP2019505488A (ja) * | 2015-12-10 | 2019-02-28 | メディミューン，エルエルシー | 免疫介在性がん治療薬に対して応答性を示す患者の治療および選択のための方法 |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
-
2018
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Application Discontinuation
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Application Discontinuation
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en unknown
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en active Pending
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA47509A (fr) | 2019-12-25 |
| KR20230145547A (ko) | 2023-10-17 |
| JP2020507596A (ja) | 2020-03-12 |
| IL268460A (en) | 2019-09-26 |
| US20190359715A1 (en) | 2019-11-28 |
| JP2024038034A (ja) | 2024-03-19 |
| AU2018221822A1 (en) | 2019-09-26 |
| KR20190117014A (ko) | 2019-10-15 |
| CA3052652A1 (en) | 2018-08-23 |
| EP3582805A1 (en) | 2019-12-25 |
| IL302777A (en) | 2023-07-01 |
| EP3582805A4 (en) | 2021-03-10 |
| SG11201907211TA (en) | 2019-09-27 |
| US20220332828A1 (en) | 2022-10-20 |
| CN110290803A (zh) | 2019-09-27 |
| WO2018152415A1 (en) | 2018-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| CY1122642T1 (el) | Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
| CO2017001317A2 (es) | Composición farmacéutica con anticuerpos anti cd40 y kit | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| BR112016005303A2 (pt) | anticorpos anti-b7-h1 para tratamento de tumores | |
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| MX2020009862A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
| MX2016009444A (es) | Anticuerpos humanos a ligando de muerte programada 1 (pd-l1). | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| MX2020009037A (es) | Anticuerpos de b7-h4 y métodos para usarlos. | |
| EA201992575A1 (ru) | Биомаркеры для терапии рака | |
| MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
| EA201991870A1 (ru) | Лечение рака мочевого пузыря с помощью антитела к pd-l1 | |
| PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
| MX2021003214A (es) | Metodos terapeuticos y de diagnostico para el cancer de vejiga. | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| PH12020551451A1 (en) | Anti-cd25 for tumour specific cell depletion | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| EA201992522A1 (ru) | КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| BR112022001037A2 (pt) | Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5 | |
| BR112022010907A2 (pt) | Uso de isatuximab para o tratamento de mieloma múltiplo recidivante e/ou refratário |